share_log

白云山(600332.SH):子公司获得药品补充申请批件

Baiyunshan (600332.SH): The subsidiary has received approval for the supplementary pharmaceutical application.

Gelonghui Finance ·  Nov 21 18:19

On November 21, GeLongHui reported that Baiyunshan (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd (referred to as 'Zhongyi Pharmaceutical'), has received the 'Drug Supplementary Application Approval Notice' issued by the National Medical Products Administration. Zhongyi Pharmaceutical submitted the supplementary application for this pharmaceutical to the National Medical Products Administration on October 22, 2024, and it was accepted on October 25, 2024. Compound Cold Capsules are used for fever due to wind-heat cold, slight aversion to cold, headache, dry mouth and thirst, nasal congestion with turbid discharge, swollen and painful throat, cough, thick yellow sputum. This pharmaceutical was originally a combination of Chinese and Western medicine formulations of the subsidiary Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd (referred to as 'Qixing Pharmaceutical'), and is an exclusive dosage form variety.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment